Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG antibody On track to initiate a randomized adaptive ...

Immunis, Inc., a clinical-stage biotech developing multi-active biologics for age and disease-related immune dysregulation, ...

On November 5, 2024, Adial announced the appointment of Vinay Shah as the Company’s Chief Financial Officer. Mr. Shah is an accomplished Chief Financial Officer with over 25 years of experience in the ...

Health Affairs' Senior Deputy Editor Rob Lott interviews Jihye Han of Brigham and Women's Hospital and Harvard University on ...

Q4 2024 Earnings Call Transcript March 3, 2025 Mersana Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.11 ...

Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.

NEW YORK, March 04, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully hu ...

AbbVie (NYSE: ABBV) and Gubra A/S (CPSE:GUBRA), a company specializing in preclinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, today ...

An expanded clinical trial that tested an experimental stem cell treatment for blinding cornea injuries found the treatment ...

A new stem cell therapy, CALEC, has demonstrated a 92% success rate in regenerating corneas and restoring vision. This ...

We reduced our fair value estimate to $15.50 per share from $27.20 to account for greater headwinds as a newly stand-alone company since its spinoff from Labcorp in 2023, which will weigh on revenue ...

CStone Pharmaceuticals ('CStone', HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the first patient ...